Skip to content
Actividades SEIMC

An update on SARS-CoV-2 and COVID-19 (Deferred)


Curso
Soporte 3ways
La inscripción para esta curso está actualmente cerrada.

Acerca de

INFORMATION

 

 

 

MODERATORS

Dr. Benito Almirante 

Director of Infectious Diseases Division. Hospital Vall d'Hebron, Barcelona. 

Dr. Rafael Delgado 

Microbiology Service. Hospital 12 de Octubre, Madrid. 

 PROGRAM


Microbiological Diagnosis.

Dr. Jordi Vila Estapé.

SEIMC. President. Head of Microbiology Service. Hospital Clínic, Barcelona.


How Can Remdesivir or Tocilizumab Help In Treating COVID-19?

Dr. Jose M. Miró.

Consultant Infectious Diseases Service. Associate Professor of Medicine. Hospital Clinic - IDIBAPS. University of Barcelona. 


Virological Assessment of Hospitalized Cases.

Dr. Roman Woelfel.

Institute Director Bundeswehr Institute of Microbiology, Germany. 


COVID-19 Illness in Native and Immunosuppressed States.

Dr. Mandeep R. Mehra.

Department of Internal Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.


Clinical Features: Predictors of Outcome.

Dr. Zheng Xin.

Infections department of Wuhan Union Medical College Hospital. 


COVID-19: Could Hydroxychloroquine Really be the Answer?

Dr. Oriol Mitjà. 

Associate Professor and Head of the STI unit at the Germans Trias i Pujol Hospital and associate researcher at ISGlobal, Barcelona. 


Pathogenicity of SARS-CoV-19. 

Dr. Adolfo García Sastre.

Icahn School Of Medicine, Mont Sinai, New York, USA.


Combining Antiviral and Anti-Inflammatory Drugs To Treat COVID-19. 

Dr. Justin Stebbing. 

Imperial College, London, UK. 

Dr. Peter Richardson. 

Imperial College, London, UK. 


Effect Of Non-Pharmaceutical Interventions For Containing the COVID-19 Outbreak In China. 

Dr. Shengjie Lai.  

Senior Research Fellow, WorldPop, School of Geography and Environment. University of Southampton, UK. 

 


An activity of: In collaboration with: 

   

 

La responsabilidad sobre el programa científico de esta actividad recae de forma individual en SEIMC que ha sido la entidad que ha seleccionado los contenidos y los ponentes. Gilead Sciences, S.L.U., no ha intervenido en ningún aspecto relacionado con la elaboración de este programa científico. Su participación en la actividad se ha limitado a financiar su realización mediante un convenio de colaboración de conformidad con la Ley 49/2002

De atrás hacia delante